APYX - Apyx Medical EPS beats by $0.12 beats on revenue; outlook

Apyx Medical (APYX): Q4 GAAP EPS of -$0.04 beats by $0.12.Revenue of $11.5M (+37.2% Y/Y) beats by $1.23M.FY2021 guidance: Total revenue in the range of $36.7M- 38.7M, representing growth of 32% to 40% Y/Y, compared to $27.7M for the year ended December 31, 2020 vs. consensus of $39.65M.Advanced Energy revenue in the range of ~$32.3M-34.3M, representing growth of 45% to 55% Y/Y, compared to $22.2M for the year ended December 31, 2020.OEM revenue of ~$4.4M, representing a decline of 20% Y/Y, compared to $5.5M for the year ended December 31, 2020.Net loss in the range of $20.7M-18.4M vs. $11.9M for the year ended December 31, 2020.Adjusted EBITDA loss in the range of $14.6M-12.0M, compared to adjusted EBITDA loss of $14.5M for the year ended December 31, 2020.Press Release

For further details see:

Apyx Medical EPS beats by $0.12, beats on revenue; outlook